SARS-CoV2-CTLS

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameSARS-CoV2-CTLS

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy

Mechanisms of ActionCytotoxic T lymphocytes replacements

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesNew York Medical College

China Registration ClassN/A

Develop Information

Active CompaniesNew York Medical College

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A